Effects of free fatty acids on the serum protein binding of flurbiprofen

Effects of free fatty acids on the serum protein binding of flurbiprofen - Protein binding of flurbiprofen and fatty acids

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025366

Enrollment

Registered

2017-01-10

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Drug 1:Flurubiprofen axetil 50 mg Drug 2:Glucose 75g (TRELAN-G75) Day1 After the 10 hours fasting in the night, drug 1 is given. Day2 After the 10 hours fasting in the night, drug 2 is given. Aft

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Healthy adults with age at obtaining informed consent of equal to or older than 20 years and youngerthan45 years. 2)Healthy adults who give informed consent regarding the participation to this strudy.

Exclusion criteria

Exclusion criteria: 1)Healthy adults with contraindication to drugs used in this study. 2)Healthy adults who are disqualified by physician(s).

Design outcomes

Primary

Measure	Time frame
Healthy adults are received intravenous injection of flurubiprofen twice (1) after the fasting more than 10 hours in the night, and (2) one hour after taking the 75 g of glucose after the fasting more than 10 hours in the night. In both groups, serum concentrations of free and total (free and serum protein bound) flurubiprofen and fatty acids were measured and compared. The study is performed with one group 2 periods cross over design (fixed sequential design). Primary endpoint is the difference in serum free flurubiprofen concentrations in alpha-phase between 2 treatments.	—

Measure

Time frame

Healthy adults are received intravenous injection of flurubiprofen twice (1) after the fasting more than 10 hours in the night, and (2) one hour after taking the 75 g of glucose after the fasting more than 10 hours in the night. In both groups, serum concentrations of free and total (free and serum protein bound) flurubiprofen and fatty acids were measured and compared. The study is performed with one group 2 periods cross over design (fixed sequential design). Primary endpoint is the difference in serum free flurubiprofen concentrations in alpha-phase between 2 treatments.

—

Secondary

Measure	Time frame
Secondary endpoint is to examine the properties of serum protein binding in each subject.	—

Countries

Japan

Contacts

Public Contactken-ichi Fujita

Showa University Institute of Molecular Oncology

k.fujita@med.showa-u.ac.jp03-3784-8146

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026